WallStreetZenWallStreetZen

NYSEMKT: AIM
Aim Immunotech Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AIM

Based on 1 analyst offering 12 month price targets for Aim Immunotech Inc

Min Forecast
$9.00+3,603.7%
Avg Forecast
$9.00+3,603.7%
Max Forecast
$9.00+3,603.7%

Should I buy or sell AIM stock?

Based on 1 analyst offering ratings for Aim Immunotech Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AIM stock forecasts and price targets.

AIM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-01

1 of 1

Forecast return on equity

Is AIM forecast to generate an efficient return?

Company
230.28%
Industry
15.61%
Market
167.44%
AIM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AIM forecast to generate an efficient return on assets?

Company
140.08%
Industry
23.94%
AIM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AIM earnings per share forecast

What is AIM's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.91
Avg 2 year Forecast
-$1.19
Avg 3 year Forecast
-$0.71

AIM revenue forecast

What is AIM's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$61.6k-35.15%
Avg 2 year Forecast
$101.0k+6.32%
Avg 3 year Forecast
$50.5k-46.84%
AIM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AIM revenue growth forecast

How is AIM forecast to perform vs Biotechnology companies and vs the US market?

Company
-13.38%
Industry
33.58%
Market
13.51%
AIM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AIM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AIM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AIM$0.22$9.00+3,990.91%Buy
CVKD$1.87$13.00+595.19%Buy
PCSA$2.43N/AN/A
CURX$0.22N/AN/A
ENVB$1.54N/AN/A
View Top Biotech Stocks

Aim Immunotech Stock Forecast FAQ

Is Aim Immunotech Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: AIM) stock is to Buy AIM stock.

Out of 1 analyst, 0 (0%) are recommending AIM as a Strong Buy, 1 (100%) are recommending AIM as a Buy, 0 (0%) are recommending AIM as a Hold, 0 (0%) are recommending AIM as a Sell, and 0 (0%) are recommending AIM as a Strong Sell.

If you're new to stock investing, here's how to buy Aim Immunotech stock.

What is AIM's earnings growth forecast for 2026-2027?

(NYSEMKT: AIM) Aim Immunotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.63%.

Aim Immunotech's earnings in 2026 is -$14,270,000.On average, 3 Wall Street analysts forecast AIM's earnings for 2026 to be -$27,671,904, with the lowest AIM earnings forecast at -$34,904,957, and the highest AIM earnings forecast at -$20,137,475. On average, 3 Wall Street analysts forecast AIM's earnings for 2027 to be -$36,280,941, with the lowest AIM earnings forecast at -$43,854,945, and the highest AIM earnings forecast at -$28,448,179.

In 2027, AIM is forecast to generate -$21,677,847 in earnings, with the lowest earnings forecast at -$26,551,634 and the highest earnings forecast at -$16,621,408.

What is AIM's revenue growth forecast for 2026-2027?

(NYSEMKT: AIM) Aim Immunotech's forecast annual revenue growth rate of -13.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.

Aim Immunotech's revenue in 2026 is $95,000.On average, 3 Wall Street analysts forecast AIM's revenue for 2026 to be $1,875,540, with the lowest AIM revenue forecast at $656,333, and the highest AIM revenue forecast at $3,196,425. On average, 2 Wall Street analysts forecast AIM's revenue for 2027 to be $3,074,656, with the lowest AIM revenue forecast at $2,983,330, and the highest AIM revenue forecast at $3,196,425.

In 2027, AIM is forecast to generate $1,537,328 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,196,425.

What is AIM's forecast return on assets (ROA) for 2026-2029?

(NYSEMKT: AIM) forecast ROA is 140.08%, which is higher than the forecast US Biotechnology industry average of 37.36%.

What is AIM's Price Target?

According to 1 Wall Street analyst that have issued a 1 year AIM price target, the average AIM price target is $9.00, with the highest AIM stock price forecast at $9.00 and the lowest AIM stock price forecast at $9.00.

The Wall Street analyst predicted that Aim Immunotech's share price could reach $9.00 by Jun 1, 2027. The average Aim Immunotech stock price prediction forecasts a potential upside of 3,990.91% from the current AIM share price of $0.22.

What is AIM's Earnings Per Share (EPS) forecast for 2026-2027?

(NYSEMKT: AIM) Aim Immunotech's current Earnings Per Share (EPS) is -$3.13. On average, analysts forecast that AIM's EPS will be -$0.91 for 2026, with the lowest EPS forecast at -$1.15, and the highest EPS forecast at -$0.66. On average, analysts forecast that AIM's EPS will be -$1.19 for 2027, with the lowest EPS forecast at -$1.44, and the highest EPS forecast at -$0.93. In 2027, AIM's EPS is forecast to hit -$0.71 (min: -$0.87, max: -$0.55).

What is AIM's forecast return on equity (ROE) for 2026-2029?

(NYSEMKT: AIM) forecast ROE is 230.28%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.